vab-1 mutants are defective in many aspects of neural and epidermal morphogenesis, including ventral epidermal enclosure during embryogenesis and in neuroblast migrations following gastrulation.
vab-1 encodes an Eph Receptor Tyrosine Kinase (RTK) (George et al., Cell 92: 633, 1998). Eph receptors are the largest subfamily of vertebrate RTK and are important in directing axonal guidance and morphogenesis in vertebrates. Based on the expression pattern of VAB-1::GFP constructs and genetic mosaic analysis, VAB-1 may function in the nervous system during embryonic morphogenesis. We are further examining where VAB-1 function is necessary and how VAB-1 signaling affects epidermal and neural development. Our previous genetic mosaic analysis suggested that VAB-1 functions in neural cells for normal epidermal morphogenesis. A caveat to this genetic mosaic analysis was that embryonic phenotypes were not assessed. A
vab-1 cDNA expressed under the control of the pan-neural
unc-119 promoter can rescue the embryonic phenotypes of
vab-1 null mutants. Thus,
vab-1 expression in neurons is sufficient for normal epidermal development. We have also created a dominant-negative (DN) version of VAB-1 by deleting the intracellular domain of the receptor. Animals that express this VAB-1DN construct under the control of the
unc-119 promoter display embryonic mutant phenotypes similar to those of strong
vab-1 alleles. If this VAB-1DN construct acts via inhibition of normal VAB-1 signaling pathways, then
vab-1 function in neurons may be necessary for normal embryonic morphogenesis. To further understand how VAB-1 signaling controls morphogenesis, we are seeking additional components of the VAB-1 signal transduction pathway. Eph RTKs are activated by binding Ephrin ligands. Several proteins that bind to activated Eph receptors have been identified by biochemical approaches, such as the adaptor protein Nck (Holland et al., EMBO J. 16: 3877, 1997); however, the roles of such proteins in vivo are poorly understood. We are testing whether C. elegans homologs of such proteins interact with VAB-1 using the yeast two-hybrid system. We are also using the two-hybrid system to screen for new VAB-1-binding proteins. We are also designing genetic screens to identify genes that act downstream of the VAB-1 kinase. We have constructed a constitutively activated version of the VAB-1 receptor by replacing the extracellular ligand-binding domain with the lambda repressor dimerization domain. This should cause ligand-independent dimerization and constitutive activation of VAB-1 kinase-dependent pathways. We are testing various promoters to drive this construct to produce a phenotype with which we will be able to screen for downstream effectors of Eph signal transduction.